On December 9, 2021, William Brown, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021. Mr. Brown is leaving the Company in order to pursue other opportunities and his decision to resign was not the result of any disagreement with the Company. On December 13, 2021, the Company announced the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s principal accounting officer and principal financial officer. Prior to joining the Company, Mr. Eisenstadt served as Chief Financial Officer, Secretary and Treasurer of Aytu BioPharma, Inc. since March 2021, when Aytu BioPharma, Inc. completed a merger with Neos Therapeutics, Inc., where Mr. Eisenstadt served as Chief Financial Officer from May 2014 until the merger in March 2021. Prior to that, Mr. Eisenstadt served as Chief Financial Officer of ArborGen Inc. from January 2013 to May 2014, and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc. from June 2003 to December 2012.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE, INC. 
